NCT02132169View on ClinicalTrials.gov

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Atopic Disease (Including Allergic Conjunctivitis)
Interventions
DRUG

Drug: AC-170 0.24%

DRUG

AC-170 0%

Trial Locations (1)

01810

Ora, Inc., Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT02132169 - A Multi-Center Study Evaluating the Safety of AC-170 0.24% | Biotech Hunter | Biotech Hunter